The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer
The Lancet Regional Health - Western Pacific · 2025-06 · 59 · 101595
DOI: 10.1016/j.lanwpc.2025.101595 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-06. Verfasst von Emma Sanderson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Circulating tumor DNA (ctDNA) testing has the potential to dramatically impact our approach to cancer management. This minimally invasive test, with potential for repeated testing, can track dynamic changes in tumour volume and molecular profile. Studies in early-stage colorectal cancer have confirmed utility in guiding adjuvant therapy decisions and studies across multiple tumour types, most notably lung cancer, have demonstrated utility in molecular characterisation.1–3 Along with confirming the clinical utility through carefully conducted prospective studies, in parallel there needs to be an ongoing focus on optimising testing methodology and confirming cost effectiveness, both being essential to ensuring broad uptake and maximal gains for patients that are affordable to the health system.
Autor:innen und Institutionen
- Division of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia.
- Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Zitieren
APA
Sanderson, E., Gibbs, P., & Tie, J. (2025). The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health - Western Pacific, 59, 101595. https://doi.org/10.1016/j.lanwpc.2025.101595
Vancouver
Sanderson E, Gibbs P, Tie J. The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer. The Lancet Regional Health - Western Pacific. 2025;59:101595. doi:10.1016/j.lanwpc.2025.101595
BibTeX
@article{Sanderson2025,
author = {Sanderson, Emma and Gibbs, Peter and Tie, Jeanne},
title = {The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer},
journal = {The Lancet Regional Health - Western Pacific},
year = {2025},
volume = {59},
pages = {101595},
doi = {10.1016/j.lanwpc.2025.101595}
}
EUVIMED